Interest of Famotidine in Children With Sickle Cell Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this study is to determine whether oral famotidine, a histamine type 2 receptor antagonist already widely used with very few side effects in other indications in children, is effective in reducing endothelial expression of P-selectin in children with sickle cell disease (SCD). This pilot study will constitute the essential prerequisite for a randomized clinical trial comparing the efficacy of famotidine with that of placebo in the prevention of vaso-occlusive crises in SCD patients.
Epistemonikos ID: 2dc76c657b9a9d8693dd9a322596a32390d65bc2
First added on: May 09, 2024